Giovanni de Gaetano was appointed Director of the Laboratory of Cardiovascular Clinical Pharmacology at Mario Negri Institute, Milan, while being still a post-doc fellow. At the end of the Eighties, he moved to the Abruzzo region, in Central Southern Italy, where he was a co-founder and first Director of a new research institute, the Mario Negri Sud. He was then appointed in 2002 Director of the Research Laboratories at the “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences of the Catholic University, Campobasso. Since 2013, he was Head of the Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) and is presently President of the Board of Neuromed.

Author of more than 530 peer-reviewed publications (Pubmed), with a H-index of 79 and more than 27,000 citations; his major scientific contributions are related to low-dose aspirin as an antiplatelet and antithrombotic drug and to the characterization of moderate wine and beer consumption (in the context of a Mediterranean Diet) as associated with reduced cardiovascular outcomes and all-cause mortality.

His combined interests  go from clinical epidemiology of risk factors for cerebrovascular and cardiovascular disease and cancer (the Moli-sani Study, www.moli-sani.org), epidemiology of food, nutrition and health, with emphasis on the Mediterranean Diet and alcoholic beverages (wine and beer), to physiopathology, biochemistry and pharmacology of blood platelets and vascular cells, clinical pharmacology and pharmacogenetics of aspirin, other antiplatelet drugs and natural polyphenols and science communication.

https://orcid.org/0000-0002-7823-1402

ABSTRACT